Necrosis binding of Ac-Lys
800CW-TATE
Fluorescent molecular probes
Molecular fluorescence-guided surgery
Necrosis-avidity
Somatostatin receptor subtype 2
Journal
EJNMMI research
ISSN: 2191-219X
Titre abrégé: EJNMMI Res
Pays: Germany
ID NLM: 101560946
Informations de publication
Date de publication:
10 May 2021
10 May 2021
Historique:
received:
03
03
2021
accepted:
30
04
2021
entrez:
10
5
2021
pubmed:
11
5
2021
medline:
11
5
2021
Statut:
epublish
Résumé
There is a growing body of nuclear contrast agents that are repurposed for fluorescence-guided surgery. New contrast agents are obtained by substituting the radioactive tag with, or adding a fluorescent cyanine to the molecular structure of antibodies or peptides. This enables intra-operative fluorescent detection of cancerous tissue, leading to more complete tumor resection. However, these fluorescent cyanines can have a remarkable influence on pharmacokinetics and tumor uptake, especially when labeled to smaller targeting vectors such as peptides. Here we demonstrate the effect of cyanine-mediated dead cell-binding of Ac-Lys Binding of 800CW-TATE could be blocked with DOTA This study shows that labeling peptides with cyanines can result in dead cell binding. This does not hamper the ultimate purpose of fluorescence-guided surgery, as necrotic tissue appears in most solid tumors. Hence, the necrosis binding can increase the overall tumor uptake. Moreover, necrotic tissue should be removed as much as possible: it cannot be salvaged, causes inflammation, and is tumorigenic. However, when performing binding experiments to cells with disrupted membrane integrity, which is routinely done with nuclear probes, this dead cell-binding can resemble non-specific binding. This study will benefit the development of fluorescent contrast agents.
Sections du résumé
BACKGROUND
BACKGROUND
There is a growing body of nuclear contrast agents that are repurposed for fluorescence-guided surgery. New contrast agents are obtained by substituting the radioactive tag with, or adding a fluorescent cyanine to the molecular structure of antibodies or peptides. This enables intra-operative fluorescent detection of cancerous tissue, leading to more complete tumor resection. However, these fluorescent cyanines can have a remarkable influence on pharmacokinetics and tumor uptake, especially when labeled to smaller targeting vectors such as peptides. Here we demonstrate the effect of cyanine-mediated dead cell-binding of Ac-Lys
RESULTS
RESULTS
Binding of 800CW-TATE could be blocked with DOTA
CONCLUSION
CONCLUSIONS
This study shows that labeling peptides with cyanines can result in dead cell binding. This does not hamper the ultimate purpose of fluorescence-guided surgery, as necrotic tissue appears in most solid tumors. Hence, the necrosis binding can increase the overall tumor uptake. Moreover, necrotic tissue should be removed as much as possible: it cannot be salvaged, causes inflammation, and is tumorigenic. However, when performing binding experiments to cells with disrupted membrane integrity, which is routinely done with nuclear probes, this dead cell-binding can resemble non-specific binding. This study will benefit the development of fluorescent contrast agents.
Identifiants
pubmed: 33970376
doi: 10.1186/s13550-021-00789-4
pii: 10.1186/s13550-021-00789-4
pmc: PMC8110618
doi:
Types de publication
Journal Article
Langues
eng
Pagination
47Subventions
Organisme : KWF Kankerbestrijding (NL)
ID : 11089-2017/1
Références
Br J Cancer. 2016 Jun 14;114(12):1334-42
pubmed: 27195424
Br J Cancer. 2010 Sep 28;103(7):1057-65
pubmed: 20736942
Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):103-14
pubmed: 26971847
Mol Imaging Biol. 2020 Oct;22(5):1333-1341
pubmed: 32514888
Exp Mol Pathol. 2012 Dec;93(3):302-8
pubmed: 23036471
Lancet Oncol. 2021 May;22(5):e186-e195
pubmed: 33765422
EJNMMI Radiopharm Chem. 2017;2(1):15
pubmed: 29503856
Curr Radiopharm. 2016;9(1):8-18
pubmed: 25771369
J Biomed Opt. 2018 Oct;23(10):1-9
pubmed: 30291698
Oncotarget. 2015 Nov 24;6(37):39676-91
pubmed: 26485755
Oncotarget. 2015 Nov 17;6(36):39036-49
pubmed: 26472022
Chem Commun (Camb). 2020 Apr 30;56(34):4672-4675
pubmed: 32211623
J Nucl Med. 2021 Mar;62(3):342-347
pubmed: 32680922
J Surg Res. 2020 Jun;250:53-58
pubmed: 32018143
Neurosurg Rev. 2019 Dec;42(4):799-809
pubmed: 30519770
Front Pharmacol. 2019 May 14;10:510
pubmed: 31139085
Front Oncol. 2016 Oct 21;6:221
pubmed: 27818949
J Nucl Med. 2016 Aug;57(8):1289-95
pubmed: 27127222
Ann Surg Oncol. 2018 Jul;25(7):1880-1888
pubmed: 29667116
Eur J Pharm Biopharm. 2016 Jul;104:226-34
pubmed: 27179587
J Neurooncol. 2021 Mar 26;:
pubmed: 33768405
J Nucl Med. 2017 Oct;58(10):1609-1614
pubmed: 28450563
J Nucl Med. 2015 Dec;56(12):1809-12
pubmed: 26514175
Oxid Med Cell Longev. 2018 Jan 31;2018:3537471
pubmed: 29636841
Theranostics. 2016 Jul 18;6(11):1821-32
pubmed: 27570553
Pancreas. 2016 Nov;45(10):1386-1393
pubmed: 27622342
Autoimmunity. 2007 Jun;40(4):285-9
pubmed: 17516211
J Biomed Opt. 2019 Jun;24(6):1-9
pubmed: 31254333
Mol Imaging Biol. 2016 Dec;18(6):905-915
pubmed: 27277828